| アブストラクト | INTRODUCTION: Due to the risk of overdoses increase especially with methadone, a reinforced monitoring has been set up by the French Addictovigilance Network following the first lockdown related to coronavirus disease 2019 (COVID-19). In this context, we managed a specific study to analyze overdoses related to methadone in 2020 compared to 2019. MATERIAL AND METHODS: We analyzed methadone-related overdoses which occurred in 2019 and 2020 from two sources: DRAMES program (deaths with toxicological analysis) and the French pharmacovigilance database (BNPV) (overdoses that did not lead to death). RESULTS: Data from DRAMES program in 2020 show methadone as the first drug involved in deaths as well as an increase in deaths: in number (n=230 versus n=178), in proportion (41% versus 35%) and number of deaths per 1000 exposed subjects (3.4 versus 2.8). According to BNPV, the number of overdose increased in 2020 compared to 2019 (98 versus 79; i.e., 1.2-fold increase) particularly during several target periods: first lockdown, end of lockdown/summer period and second lockdown. In 2020, a higher number of cases were observed in April (n=15) and May (n=15). Overdoses and deaths occurred in subjects enrolled in treatment programs or not (naive subjects/occasional users who obtained methadone from street market or family/friends). Overdoses resulted from different factors: overconsumption, multiple drug use with depressants drugs or cocaine, injection, consumption for sedative, recreational purposes or voluntary drug poisoning. DISCUSSION/CONCLUSION: All these data show an increase of morbidity and mortality related to methadone during COVID-19 epidemic. This trend has been observed in other countries. |
|---|
| 投稿者 | Frauger, Elisabeth; Fouilhe, Nathalie; Lacroix, Clemence; Daveluy, Amelie; Le Boisselier, Reynald; Bertin, Celian; Revol, Bruno; Carton, Louise; Chevalier, Cecile; Eiden, Celine; Gibaja, Valerie; Aquizerate, Aurelie; Chaouachi, Leila; Bouquet, Emilie; Roussin, Anne; Mallaret, Michel; Micallef, Joelle |
|---|
| 組織名 | Centre d'addictovigilance, service de pharmacologie clinique, hopital de la;Timone, Assistance publique-Hopitaux de Marseille, Aix-Marseille universite,;institut de neurosciences des systemes, Inserm UMR1106, 13005 Marseille, France.;Electronic address: elisabeth.frauger@ap-hm.fr.;Centre d'addictovigilance, CHU de Grenoble-Alpes, 38043 Grenoble, France.;Centre d'addictovigilance, departement de pharmacologie, hopital Pellegrin, CHU;de Bordeaux, 33076 Bordeaux, France.;Centre d'addictovigilance, service de pharmacologie, CHU de Caen, 14033 Caen,;France.;Centre d'addictovigilance, service de pharmacologie medicale, CHU de;Clermont-Ferrand, universite Clermont Auvergne, 63003 Clermont-Ferrand, France.;Centre d'addictovigilance, service de pharmacologie, faculte de medecine-pole;recherche, 59037 Lille, France.;Centre d'addictovigilance, service hospitalo-universitaire de;pharmacotoxicologie, hospices civils de Lyon, 69424 Lyon cedex, France.;Centre d'addictovigilance, departement de pharmacologie medicale et toxicologie,;hopital Lapeyronie, CHU de Montpellier, 34295 Montpellier, France.;Centre d'addictovigilance, CHRU de Nancy, hopital Brabois, 54511;Vandoeuvre-les-Nancy, France.;Centre d'addictovigilance, service de pharmacologie clinique, institut de;biologie, CHU de Nantes, 44093 Nantes, France.;Centre d'addictovigilance, hopital Fernand-Widal, 75475 Paris, France.;Centre d'addictovigilance, service de pharmacologie clinique et vigilances, CHU;de Poitiers, 86021 Poitiers, France.;Centre d'addictovigilance, faculte de medecine, 31000 Toulouse, France. |
|---|
